An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels - Concepedia

Concepedia

Publication | Closed Access

An open-label trial in Friedreich ataxia suggests clinical benefit with high-dose resveratrol, without effect on frataxin levels

110

Citations

31

References

2015

Year

Eppie M. Yiu, Geneieve Tai, Roger E. Peverill, Katherine J. Lee, Kevin D. Croft, Trevor A. Mori, Barbara Scheiber‐Mojdehkar, Brigitte Sturm, Monika Praschberger, Adam P. Vogel,

Journal of Neurology

Open-label TrialPharmacologyClinical TrialsFrataxin LevelsClinical BenefitNeurologyMedicineOxidative Stress

References

	Year	Citations

Page 1

Page 1